Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...

Some people won't mind if you keep your screen visible, but that doesn't mean you should let yourself be distracted. Jason Chun is a CNET writer covering a range of topics in tech, home, wellness, ...